研究单位：[1]Sun Yat-sen University,Sun Yat-sen University[2]Qilu Pharmaceutical Co., Ltd.[3]Fujian Cancer Hospital,Fuzhou 1810821,Fujian 1811017,China[4]Dongguan People''s Hospital,Dongguan 1812545,Guangdong 1809935,China[5]First People''s Hospital of Foshan,Foshan 1811103,Guangdong 1809935,China[6]Guangzhou Panyu Central Hospital,Guangzhou 1809858,Guangdong 1809935,China,510060[7]Sun Yat-Sen University Cancer Center,Guangzhou 1809858,Guangdong 1809935,China,510060[8]Zhongshan People''s Hospital,Zhongshan 6986104,Guangdong 1809935,China[9]Cancer Hospital of Guangxi Medical University,Nanning 1799869,Guangxi 1809867,China,530000[10]Cancer Hospital of Guizhou Medical University,Guiyang 1809461,Guizhou 1809445,China[11]Hubei Province Cancer Hosiptal,Wuhan 1791247,Hubei 1806949,China,430000[12]Renmin Hospital of Wuhan University,Wuhan 1791247,Hubei 1806949,China,430000[13]Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology,Wuhan 1791247,Hubei 1806949,China,430000[14]Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology,Wuhan 1791247,Hubei 1806949,China,430000[15]Hunan Cancer Hospital,Changsha 1815577,Hunan 1806691,China,410000[16]Xiangya Hospital of Central South University,Changsha 1815577,Hunan 1806691,China[17]Jiangsu Cancer Hospital,Nanjing 1799962,Jiangsu 1806260,China,210000[18]The Eye and ENT Hospital of Fudan University,Shanghai 1796236,Shanghai Municipality 1796231,China,200000[19]Sichuan Cancer Hospital,Chengdu 1815286,Sichuan 1794299,China,610001[20]Tianjin Medical University Cancer Institute ＆ Hospital,Tianjin 1792947,Tianjin Municipality 1792943,China,30000[21]The First Affiliated Hospital of Xiamen University,Fujian 8422032,Xiamen,China,361000
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
